GOLDMAN SACHS GROUP INC - ARATANA THERAPEUTICS INC ownership

ARATANA THERAPEUTICS INC's ticker is PETX and the CUSIP is 03874P101. A total of 104 filers reported holding ARATANA THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ARATANA THERAPEUTICS INC
ValueSharesWeighting
Q2 2019$4,241,000
+1958.7%
821,902
+1337.6%
0.00%
Q1 2019$206,000
-90.5%
57,172
-83.8%
0.00%
-100.0%
Q4 2018$2,170,000
-39.0%
353,961
-41.9%
0.00%0.0%
Q3 2018$3,555,000
+612.4%
608,792
+418.4%
0.00%
Q2 2018$499,000
-79.5%
117,441
-78.8%
0.00%
-100.0%
Q1 2018$2,438,000
+581.0%
552,783
+712.5%
0.00%
Q4 2017$358,000
+15.9%
68,039
+35.1%
0.00%
Q3 2017$309,000
+22.6%
50,362
+44.6%
0.00%
Q2 2017$252,000
-27.4%
34,834
-46.7%
0.00%
Q1 2017$347,000
-19.9%
65,415
+8.6%
0.00%
Q4 2016$433,000
-43.0%
60,250
-25.7%
0.00%
Q3 2016$759,000
+377.4%
81,057
+221.3%
0.00%
Q2 2016$159,000
+98.8%
25,227
+73.8%
0.00%
Q1 2016$80,000
-73.2%
14,514
-72.8%
0.00%
Q4 2015$298,000
+242.5%
53,345
+420.2%
0.00%
Q3 2015$87,000
-98.3%
10,254
-96.5%
0.00%
-100.0%
Q4 2014$5,234,000
+63.9%
293,709
-7.7%
0.00%
+100.0%
Q3 2014$3,194,000
-32.3%
318,072
+5.3%
0.00%0.0%
Q2 2014$4,716,000
-20.2%
302,107
-5.1%
0.00%
-50.0%
Q1 2014$5,909,000
+775.4%
318,392
+800.9%
0.00%
Q4 2013$675,000
-39.1%
35,343
-47.9%
0.00%
Q3 2013$1,109,00067,8900.00%
Other shareholders
ARATANA THERAPEUTICS INC shareholders Q3 2015
NameSharesValueWeighting ↓
Broadfin Capital, LLC 5,184,942$31,784,0004.70%
AWM Investment Company, Inc. 1,562,517$9,578,0001.67%
Opaleye Management Inc. 420,000$2,574,0000.91%
MPM ASSET MANAGEMENT LLC 250,000$1,533,0000.75%
GENERAL AMERICAN INVESTORS CO INC 867,600$5,318,0000.50%
Grandeur Peak Global Advisors, LLC 538,363$3,300,0000.50%
Redmond Asset Management, LLC 55,941$343,0000.16%
WOODSTOCK CORP 88,303$541,0000.10%
CADENCE CAPITAL MANAGEMENT LLC 173,808$1,065,0000.07%
Sheaff Brock Investment Advisors, LLC 71,000$435,0000.06%
View complete list of ARATANA THERAPEUTICS INC shareholders